Proof of concept and development of a couple-based machine learning model to stratify infertile patients with idiopathic infertility.

Journal: Scientific reports
Published Date:

Abstract

We aimed to develop and evaluate a machine learning model that can stratify infertile/fertile couples on the basis of their bioclinical signature helping the management of couples with unexplained infertility. Fertile and infertile couples were recruited in the ALIFERT cross-sectional case-control multicentric study between September 2009 and December 2013 (NCT01093378). The study group consisted of 97 infertile couples presenting a primary idiopathic infertility (> 12 months) from 4 French infertility centers compared with 100 fertile couples (with a spontaneously conceived child (< 2 years of age) and with time to pregnancy < 12 months) recruited from the healthy population of the areas around the infertility centers. The study group is comprised of 2 independent sets: a development set (n = 136 from 3 centers) serving to train the model and a test set (n = 61 from 1 center) used to provide an unbiased validation of the model. Our results have shown that: (i) a couple-modeling approach was more discriminant than models in which men's and women's parameters are considered separately; (ii) the most discriminating variables were anthropometric, or related to the metabolic and oxidative status; (iii) a refined model capable to stratify fertile vs. infertile couples with accuracy 73.8% was proposed after the variables selection (from 80 to 13). These influential factors (anthropometric, antioxidative, and metabolic signatures) are all modifiable by the couple lifestyle. The model proposed takes place in the management of couples with idiopathic infertility, for whom the decision-making tools are scarce. Prospective interventional studies are now needed to validate the model clinical use.Trial registration: NCT01093378 ALIFERT https://clinicaltrials.gov/ct2/show/NCT01093378?term=ALIFERT&rank=1 . Registered: March 25, 2010.

Authors

  • Guillaume Bachelot
    Service de Biologie de La Reproduction-CECOS, Hôpital Tenon, AP-HP/Sorbonne Université, 75020, Paris, France.
  • Rachel Lévy
    Service de Biologie de La Reproduction-CECOS, Hôpital Tenon, AP-HP/Sorbonne Université, 75020, Paris, France.
  • Anne Bachelot
    Department of Endocrinology and Reproductive Medicine, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Centre de Référence des Pathologies Gynécologiques Rares, ICAN, Paris, France.
  • Celine Faure
  • Sébastien Czernichow
    Université de Paris, INSERM, UMR1153, Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), METHODS team, Service de Nutrition, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
  • Charlotte Dupont
    Service de Biologie de La Reproduction-CECOS, Hôpital Tenon, AP-HP/Sorbonne Université, 75020, Paris, France.
  • Antonin Lamazière
    Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, 75012, Paris, France. antonin.lamaziere@aphp.fr.